Aptevo, Niowave form 50/50 radiopharmaceutical oncology collaboration
PUBT · 05/27 12:08
Share
Listen to the news
- Aptevo entered a 50/50 strategic collaboration with Niowave to develop up to three radiopharmaceutical oncology programs.
- Niowave made an at-the-market equity investment at closing, taking a 7.9% stake with potential to reach 19.99% via warrants and future buys.
- Initial program targets Nectin-4 using Aptevo multispecific antibody assets paired with Niowave radioisotope supply, including Actinium-225.
- Partnership expands Aptevo into radiopharmaceutical therapeutics, addressing isotope supply constraints through Niowave manufacturing and distribution capabilities.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief on May 27, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved